Hudson Bay Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-297,833
Closed -$3.13M – 1771
2026
Q1
$3.13M Sell
297,833
-1,252,167
-81% -$13.1M 0.01% 646
2025
Q4
$16.1M Hold
1,550,000
– – 0.05% 252
2025
Q3
$15.9M Sell
1,550,000
-250,000
-14% -$2.56M 0.05% 265
2025
Q2
$18.4M Hold
1,800,000
– – 0.06% 229
2025
Q1
$18M Buy
+1,800,000
New +$18M 0.06% 278

Other funds holding DMAA

Hudson Bay Capital Management's DMAA Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 297,833 shares — an estimated $3.13M sold.

Hudson Bay Capital Management first reported a position in DMAA in Q1 2025 and held it in 5 quarters. The position peaked at $18.4M in Q2 2025. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 297,833 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $3.13M.
  • Hudson Bay Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 5 quarters.
  • Hudson Bay Capital Management's Drugs Made In America Acquisition Corp position peaked at $18.4M in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.